{"id":"https://openalex.org/W2096416969","doi":"https://doi.org/10.2147/ppa.s90842","title":"Evaluating preferences for profiles of GLP-1 receptor agonists among injection-na\u00efve type 2 diabetes patients in the UK","display_name":"Evaluating preferences for profiles of GLP-1 receptor agonists among injection-na\u00efve type 2 diabetes patients in the UK","alternate_titles":[],"publication_year":2015,"publication_date":"2015-11-01","ids":{"openalex":"https://openalex.org/W2096416969","doi":"https://doi.org/10.2147/ppa.s90842","mag":"2096416969","pmid":"https://pubmed.ncbi.nlm.nih.gov/26635470","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4646588"},"language":"en","primary_location":{"id":"doi:10.2147/ppa.s90842","doi":"https://doi.org/10.2147/ppa.s90842","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ppa.s90842","pdf_url":"https://www.dovepress.com/getfile.php?fileID=27950","source":{"id":"https://openalex.org/S66639021","display_name":"Patient Preference and Adherence","issn_l":"1177-889X","issn":["1177-889X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Patient Preference and Adherence","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2096416969"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/getfile.php?fileID=27950","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039792370","display_name":"Heather L. Gelhorn","orcid":"https://orcid.org/0000-0003-3566-1004","observed_orcids":["https://orcid.org/0000-0003-3566-1004"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Heather Gelhorn","raw_affiliation_strings":["Outcomes Research, Evidera, Bethesda, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Outcomes Research, Evidera, Bethesda, MD, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048405172","display_name":"Jiat Ling Poon","orcid":"https://orcid.org/0000-0001-7038-2102","observed_orcids":["https://orcid.org/0000-0001-7038-2102"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jiat-Ling Poon","raw_affiliation_strings":["Outcomes Research, Evidera, Bethesda, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Outcomes Research, Evidera, Bethesda, MD, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108437733","display_name":"Evan W. Davies","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Evan Davies","raw_affiliation_strings":["Outcomes Research, Evidera, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Outcomes Research, Evidera, London, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055558946","display_name":"Rosirene Paczkowski","orcid":"https://orcid.org/0009-0001-7151-4311","observed_orcids":["https://orcid.org/0009-0001-7151-4311"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rosirene Paczkowski","raw_affiliation_strings":["Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, USA","Global Patient Outcomes and Real World Evidence, Eli Lilly & Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"Global Patient Outcomes and Real World Evidence, Eli Lilly & Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Sarah Curtis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sarah Curtis","raw_affiliation_strings":["Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, USA","Global Patient Outcomes and Real World Evidence, Eli Lilly & Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"Global Patient Outcomes and Real World Evidence, Eli Lilly & Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039006946","display_name":"Kristina Secnik Boye","orcid":"https://orcid.org/0000-0002-5953-5929","observed_orcids":["https://orcid.org/0000-0002-5953-5929"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kristina Secnik Boye","raw_affiliation_strings":["Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, USA","Global Patient Outcomes and Real World Evidence, Eli Lilly & Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"Global Patient Outcomes and Real World Evidence, Eli Lilly & Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5039792370"],"corresponding_institution_ids":[],"apc_list":{"value":2836,"currency":"USD","value_usd":2836},"apc_paid":{"value":2836,"currency":"USD","value_usd":2836},"fwci":4.0094,"has_fulltext":true,"cited_by_count":60,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.94345606,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"9","issue":null,"first_page":"1611","last_page":"1611"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.6118000149726868,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.6118000149726868,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10841","display_name":"Economic and Environmental Valuation","score":0.3264000117778778,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.03739999979734421,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.8569999933242798},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9570000171661377},{"id":"https://openalex.org/keywords/dulaglutide","display_name":"dulaglutide","score":0.9959999918937683},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":1.0},{"id":"https://openalex.org/keywords/patient-preferences","display_name":"patient preferences","score":0.9319999814033508},{"id":"https://openalex.org/keywords/treatment-profile","display_name":"treatment profile","score":0.5180000066757202},{"id":"https://openalex.org/keywords/dosing-frequency","display_name":"dosing frequency","score":0.8069999814033508},{"id":"https://openalex.org/keywords/drug-delivery-systems","display_name":"drug delivery systems","score":0.6620000004768372},{"id":"https://openalex.org/keywords/nausea","display_name":"nausea","score":0.7229999899864197},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.9900000095367432},{"id":"https://openalex.org/keywords/weight-change","display_name":"weight change","score":0.9079999923706055},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.902999997138977},{"id":"https://openalex.org/keywords/relative-importance","display_name":"relative importance","score":0.5989999771118164}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8484053015708923},{"id":"https://openalex.org/C2779829264","wikidata":"https://www.wikidata.org/wiki/Q21011228","display_name":"Dulaglutide","level":5,"score":0.8159691095352173},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.8030451536178589},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.7288689613342285},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6551289558410645},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.5017783641815186},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.48234623670578003},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.47162890434265137},{"id":"https://openalex.org/C2780221984","wikidata":"https://www.wikidata.org/wiki/Q131191","display_name":"Body mass index","level":2,"score":0.4618687927722931},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.45992642641067505},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.40762007236480713},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.29519638419151306},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0}],"mesh":[],"locations_count":5,"locations":[{"id":"doi:10.2147/ppa.s90842","doi":"https://doi.org/10.2147/ppa.s90842","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ppa.s90842","pdf_url":"https://www.dovepress.com/getfile.php?fileID=27950","source":{"id":"https://openalex.org/S66639021","display_name":"Patient Preference and Adherence","issn_l":"1177-889X","issn":["1177-889X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Patient Preference and Adherence","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4646588","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4646588/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Patient Prefer Adherence","raw_type":"Text"},{"id":"pmid:26635470","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26635470","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Patient preference and adherence","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:23739a95a2024888bd19c4219710d5fa","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/23739a95a2024888bd19c4219710d5fa","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Patient Preference and Adherence, Vol 2015, Iss default, Pp 1611-1622 (2015)","raw_type":"article"},{"id":"pmh:oai:dovepress.com/24555","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/evaluating-preferences-for-profiles-of-glp-1-receptor-agonists-among-i-peer-reviewed-article-PPA","pdf_url":"http://support.sas.com/techsup/technote/mr2010.pdf","source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.2147/ppa.s90842","doi":"https://doi.org/10.2147/ppa.s90842","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ppa.s90842","pdf_url":"https://www.dovepress.com/getfile.php?fileID=27950","source":{"id":"https://openalex.org/S66639021","display_name":"Patient Preference and Adherence","issn_l":"1177-889X","issn":["1177-889X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Patient Preference and Adherence","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2096416969.pdf","grobid_xml":"https://content.openalex.org/works/W2096416969.grobid-xml"},"referenced_works_count":25,"referenced_works":["https://openalex.org/W168155306","https://openalex.org/W1590210216","https://openalex.org/W1602006543","https://openalex.org/W1983171902","https://openalex.org/W1988255364","https://openalex.org/W1990187195","https://openalex.org/W1992780652","https://openalex.org/W1996879430","https://openalex.org/W1997094476","https://openalex.org/W2011998736","https://openalex.org/W2020267609","https://openalex.org/W2044834221","https://openalex.org/W2066861619","https://openalex.org/W2076583826","https://openalex.org/W2076697542","https://openalex.org/W2088998005","https://openalex.org/W2096965060","https://openalex.org/W2107680428","https://openalex.org/W2111876001","https://openalex.org/W2152984355","https://openalex.org/W2160088494","https://openalex.org/W2172193326","https://openalex.org/W2346764245","https://openalex.org/W2406523485","https://openalex.org/W4302130375"],"related_works":["https://openalex.org/W2478113780","https://openalex.org/W2922465073","https://openalex.org/W2441814170","https://openalex.org/W2585146202","https://openalex.org/W2920836114","https://openalex.org/W2938716486","https://openalex.org/W2590405401","https://openalex.org/W2543582919","https://openalex.org/W2766740654","https://openalex.org/W3110313641"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"use":[2],"a":[3,50],"discrete":[4],"choice":[5],"experiment":[6],"(DCE)":[7],"to":[8,48,52,58,106,120,284],"evaluate":[9],"preferences":[10,124,210],"for":[11,112,125,159,211,239],"the":[12,38,46,155,160,194,200,216,243],"actual":[13,217],"treatment":[14,59,70,271],"features":[15,272],"and":[16,27,90,103,185,213,230,276],"overall":[17],"profiles":[18],"of":[19,68,84,88,92,133,170,175,187,219,232,242,280],"two":[20,74,220],"injectable":[21,61],"glucagon-like":[22,222],"peptide-1":[23,223],"receptor":[24],"agonists":[25],"(dulaglutide":[26],"liraglutide)":[28],"among":[29],"patients":[30,53],"with":[31,54,60,199],"type":[32,231],"2":[33],"diabetes":[34],"mellitus":[35],"(T2DM)":[36],"in":[37,45,123,162,254,264],"UK.":[39],"METHODS:":[40],"In-person":[41],"interviews":[42],"were":[43,96,104,235],"conducted":[44],"UK":[47],"administer":[49],"DCE":[51,64],"self-reported":[55],"T2DM,":[56],"na\u00efve":[57],"medications.":[62,224],"The":[63],"examined":[65],"six":[66],"attributes":[67,161,212],"T2DM":[69,255],"each":[71,113],"described":[72],"by":[73],"levels:":[75],"\"dosing":[76,166],"frequency,\"":[77],"\"hemoglobin":[78,181],"A1c":[79,182],"change,\"":[80,82],"\"weight":[81,178],"\"type":[83,169],"delivery":[85,171,233,277],"system,\"":[86],"\"frequency":[87,91,174,186],"nausea,\"":[89],"hypoglycemia.\"":[93],"Part-worth":[94],"utilities":[95],"estimated":[97],"using":[98],"random":[99],"effects":[100],"logit":[101],"models":[102],"used":[105,119],"calculate":[107],"relative":[108],"importance":[109,283],"(RI)":[110],"values":[111,158],"attribute.":[114],"A":[115,131],"chi-square":[116],"test":[117],"was":[118],"determine":[121],"differences":[122,263],"dulaglutide":[126,195],"versus":[127],"liraglutide":[128,201],"profiles.":[129],"RESULTS:":[130],"total":[132],"243":[134],"participants":[135,192],"[mean":[136],"age:":[137],"60.5":[138],"(standard":[139,150],"deviation":[140,151],"10.9)":[141],"years;":[142],"76.1%":[143],"male;":[144],"mean":[145],"body":[146],"mass":[147],"index:":[148],"29.8":[149],"5.4)":[152],"kg/m(2)]":[153],"completed":[154],"study.":[156],"RI":[157],"rank":[163],"order":[164],"were:":[165],"frequency\"":[167],"(41.6%),":[168],"system\"":[172],"(35.5%),":[173],"nausea\"":[176],"(10.4%),":[177],"change\"":[179,183],"(5.9%),":[180],"(3.6%),":[184],"hypoglycemia\"":[188],"(3.0%).":[189],"Significantly":[190],"more":[191],"preferred":[193],"profile":[196,202],"(83.1%)":[197],"compared":[198],"(16.9%;":[203],"P<0.0001).":[204],"CONCLUSION:":[205],"This":[206],"study":[207,259],"elicited":[208],"patients'":[209],"levels":[214],"representing":[215],"characteristics":[218],"specific":[221],"In":[225],"this":[226,258],"context,":[227],"dosing":[228,274],"frequency":[229,275],"system":[234],"most":[236],"important,":[237],"accounting":[238],"over":[240],"75%":[241],"RI.":[244],"While":[245],"previous":[246],"studies":[247],"have":[248],"identified":[249],"efficacy":[250,265],"as":[251],"highly":[252],"important":[253],"medication":[256],"decisions,":[257],"suggests":[260],"that":[261],"when":[262],"between":[266],"medications":[267],"are":[268,279],"small,":[269],"other":[270],"(eg,":[273],"system)":[278],"much":[281],"greater":[282],"patients.":[285]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2096416969","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":12},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":2}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
